累计访问量:加载中...
---- -- --
---
--:--:--

浙江大学金华研究院

肖庆全实验室

致力于新一代基因编辑工具与基因治疗技术的开发。

课题组负责人

肖庆全博士现任浙江大学金华研究院、浙江大学药学院研究员,并为 Gu iMedication Lab 成员。他带领独立研究团队,致力于新一代基因编辑工具与基因治疗技术的开发。

加入浙江大学前,肖庆全博士曾在中国科学院脑科学与智能技术卓越创新中心(神经科学研究所)从事博士后研究。他于中国科学院大学获得神经生物学博士学位,博士期间在非人灵长类疾病模型实验室开展研究,并于四川大学获得生物学学士学位。

肖庆全博士入选上海市“超级博士后”激励计划。相关研究成果以第一作者、共同第一作者或共同通讯作者身份发表论文发表于 Nature Biotechnology、Nature Methods、Nature Chemical Biology、Science Translational Medicine、Advanced Science、Journal of Clinical Investigation 和 Cell Discovery 等学术期刊。此外,他还担任多种学术期刊及学术出版社的同行评审专家,参与论文和书籍章节的评审工作。

电子邮箱:qqxiao@zju.edu.cn个人主页:肖庆全微信公众号:肖庆全实验室

团队成员

肖庆全实验室团队

目前,团队由1名博士后、2名博士研究生和5名硕士研究生组成。

研究方向

代表性论文

# 表示共同第一作者;* 表示共同通讯作者。

  1. Xiao, Q.#,*, Tian, Z.#, Weng, L.#, Xu, K.#, Han, D.#, Wu, Z., Li, J., Li, S., Zhang, Q., Zhao, X., Li, G.*, Wei, Y.*, & Gu, Z.* (2026). Compact 9dBEs Enable Efficient and Precise Genome Editing in Mammalian Cells and In Vivo. Advanced Science, 13, e77279. https://doi.org/10.1002/advs.77279
  2. Xiao, Q.#, Li, G.#, Han, D.#, Wang, H.#, Yao, M.#, Ma, T., Zhou, J., Zhang, Y., Zhang, X., He, B., Yuan, Y., Shi, L., Li, T.*, Yang, H.*, Huang, J.*, & Zhang, H.* (2024). Engineered IscB-ωRNA system with expanded target range for base editing. Nature Chemical Biology, 21(1), 100–108. https://doi.org/10.1038/s41589-024-01706-1
  3. Xiao, Q.#, Xu, Z.#, Xue, Y.#, Xu, C.#, Han, L., Liu, Y., Wang, F., Zhang, R., Han, S., Wang, X., Li, G. L., Li, H.*, Yang, H.*, & Shu, Y.* (2022). Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor. Science Translational Medicine, 14(654), eabn0449. https://doi.org/10.1126/scitranslmed.abn0449
  4. Han, D.#, Xiao, Q.#, Wang, Y.#, Zhang, H.#, Dong, X., Li, G., Kong, X., Wang, S., Song, J., Zhang, W., Zhou, J., Bi, L., Yuan, Y., Shi, L., Zhong, N., Yang, H.*, & Zhou, Y.* (2023). Development of miniature base editors using engineered IscB nickase. Nature Methods, 20(7), 1029–1036. https://doi.org/10.1038/s41592-023-01898-9
  5. Tong, H.#, Huang, J.#,*, Xiao, Q.#, He, B.#, Dong, X.#, Liu, Y.#, Yang, X., Han, D., Wang, Z., Wang, X., Ying, W., Zhang, R., Wei, Y., Xu, C., Zhou, Y., Li, Y., Cai, M., Wang, Q., Xue, M., Li, G., Fang K., Zhang H.* & Yang H.* (2022). High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. Nature Biotechnology, 41(1), 108–119. https://doi.org/10.1038/s41587-022-01419-7
  6. Xu, C.#, Zhou, Y.#,*, Xiao, Q.#, He, B.#, Geng, G.#, Wang, Z., Cao, B., Dong, X., Bai, W., Wang, Y., Wang, X., Zhou, D., Yuan, T., Huo, X., Lai, J.*, & Yang, H.* (2021). Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes. Nature Methods, 18(5), 499–506. https://doi.org/10.1038/s41592-021-01124-4
  7. Li, G.#, Jin, M.#, Li, Z.#, Xiao, Q.#, Lin, J.#, Yang, D.#, Liu, Y., Wang, X., Xie, L., Ying, W., Wang, H., Zuo, E., Shi, L., Wang, N.*, Chen, W.*, Xu, C.*, & Yang, H.* (2023). Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy. The Journal of Clinical Investigation, 133(3), e162809. https://doi.org/10.1172/JCI162809
  8. Hu, X.#, Wang, J.#, Yao, X.#, Xiao, Q.#, Xue, Y., Wang, S., Shi, L., Shu, Y.*, Li, H.*, & Yang, H.* (2019). Screened AAV variants permit efficient transduction access to supporting cells and hair cells. Cell Discovery, 5, 49. https://doi.org/10.1038/s41421-019-0115-9

其他论文

# 表示共同第一作者;* 表示共同通讯作者。

  1. Guo R.#, Sun X.#, Wang F.#, Han D.#, Yang Q., Gao H., Li Z., Shao Z., Shi J., Yang R., Huo X., Yan J., Li G., Xiao Q., Liu Y., Zhang S., Liu X., Zhou Y., Wang L.*, Hu C.*, Xu C.* (2024). Engineered IscB-ωRNA system with improved base editing efficiency for disease correction via single AAV delivery in mice. Cell Reports, 43(11), 114973. https://doi.org/10.1016/j.celrep.2024.114973
  2. Xue, Y.#, Tao, Y.#, Wang, X.#, Wang, X., Shu, Y., Liu, Y., Kang, W., Chen, S., Cheng, Z., Yan, B., Xie, Y., Bi, L., Jia, H., Li, J., Xiao Q., Chen, L., Yao, X., Shi, L., Yang, H.*, & Wu, H.* (2023). RNA base editing therapy cures hearing loss induced by OTOF gene mutation. Molecular Therapy, 31(12), 3520–3530. https://doi.org/10.1016/j.ymthe.2023.10.019
  3. Gao, N.#, Hu, J.#, He, B.#, Ji, Z.#, Hu, X.#, Huang, J., Wei, Y., Peng, J., Wei, Y., Zhou, Y., Shen, X., Li, H., Feng, X., Xiao Q., Shi, L., Sun, Y., Zhou, C., Zhou, H.*, & Yang, H.* (2021). Endogenous promoter-driven sgRNA for monitoring the expression of low-abundance transcripts and lncRNAs. Nature Cell Biology, 23(1), 99–108. https://doi.org/10.1038/s41556-020-00610-9
  4. Zhang, M.#, Zhou, C.#, Wei, Y.#, Xu, C.#, Pan, H., Ying, W., Sun, Y., Sun, Y., Xiao Q., Yao, N., Zhong, W., Li, Y., Wu, K., Yuan, G., Mitalipov, S.*, Chen, Z. J.*, & Yang, H.* (2019). Human cleaving embryos enable robust homozygotic nucleotide substitutions by base editors. Genome Biology, 20(1), 101. https://doi.org/10.1186/s13059-019-1703-6
  5. Jin, M.#, Lin, J.#, Zhang, Y.#, Xiao Q., Kong, X., Zhang, X., Shao, Z., Wang, Y., Yu, Y., Li, J., Chen, W. J., Li, G.*, Yang, H.*, & Wang, N.* (2024). enOsCas12f1-mediated exon skipping for Duchenne muscular dystrophy therapy in humanized mouse model. Journal of Genetics and Genomics, 51(2), 256–259. https://doi.org/10.1016/j.jgg.2023.12.003
  6. Yan, Z.#, Yao, Y.#, Li, L.#, Cai, L., Zhang, H., Zhang, S., Xiao Q., Wang, X., Zuo, E.*, Xu, C.*, Wu, J.*, & Yang, H.* (2023). Treatment of autosomal dominant retinitis pigmentosa caused by RHO-P23H mutation with high-fidelity Cas13X in mice. Molecular Therapy – Nucleic Acids, 33, 750–761. https://doi.org/10.1016/j.omtn.2023.08.002

专利

  1. 一种Cas蛋白、融合蛋白、其相应的基因编辑系统及应用,肖庆全、顾臻、田之锦,ZL202610251120.1(中国),(第一发明人)
  2. TYPE VI-E AND TYPE VI-F CRISPR-CAS SYSTEM AND USES THEREOF. Hui Yang, Chunlong Xu, Yingsi Zhou, Qingquan Xiao. US Patent 16/864,982(美国),PCT,(共同发明人)
  3. VI-E型和VI-F型CRISPR-Cas系统及其用途,杨辉、胥春龙、周英思、肖庆全,ZL.202010390901.1(中国),(共同发明人)
  4. ISCB POLYPEPTIDES AND USES THEREOF. Hainan Zhang, Qingquan Xiao. 2025-07-17, WIPO, PCT/CN2025/072127(美国),(共同发明人)

学术报告

  1. 肖庆全;紧凑型DNA碱基编辑器的开发及应用,中国遗传学会基因组编辑分会第七届全国学术年会,湖南长沙,2026-10-15至2026-10-18(邀请报告)
  2. 肖庆全;紧凑型基因编辑器的开发及其应用,首届智能医药前沿交叉研讨会暨2025年先进药物递释系统全国重点实验室学术年会,浙江杭州,2025-11-24至2025-11-26(邀请报告)
  3. Xiao Q., Han D., Wang H., Li G., Yuan Y., Zhou Y., Li T., Wang S., Yao X., Alvin Luk, Kong X., Zhang H. and Yang H. (2024). Engineered IscB-ωRNA System with Expanded Target Range for Base Editing. ASGCT, the 27th Annual Meeting. (Invited talk)
  4. Li G., Xiao Q., Han D., Wang H., Ma T., Zhou J., Zhang Y., Zhang X., Li T., Wang S., Yuan Y., Yao Y., Shi L., Zhou Y., Zhang H. and Yang H. (2024). Precise Correction of Duchenne Muscular Dystrophy by Compact Cytosine Base Editor-Induced Exon Skipping. ASGCT, the 27th Annual Meeting. (Poster)

加入我们

We welcome highly motivated individuals interested in AI for Science, nucleic acid delivery, genome editing, therapeutics, and drug discovery to join our team.

免责声明

本网站所提供的实验室介绍、个人简介、科研活动及研究成果等内容,仅供信息参考与学术交流之用,不构成任何形式的医疗、诊断、治疗或投资建议。

本网站涉及的基因编辑技术、基因治疗及相关研究内容,反映的是相关领域持续发展的科学研究进展,不应据此认定相关技术已通过临床验证、获得监管部门批准或具备临床应用条件。本网站所载信息不能替代专业医疗意见,亦不应作为作出医疗或投资决策的依据。

我们将尽合理努力确保本网站所载信息的准确性和完整性,但不对相关信息的准确性、完整性或时效性作出任何明示或默示的保证。我们保留随时更新、修改或删除网站内容的权利,恕不另行通知。